We use cookies for a better user experience. Read our Privacy Policy
I AgreeSurge in the acceptance of AI-based technologies among different companies from pharmaceutical industry and academia is expected to create exceptional growth opportunities in the global AI-based clinical trials solution provider market during the forecast period 2021-2031.
An upcoming research report by TMR gives comprehensive analysis of major facets shaping development of the global AI-based clinical trials solution provider market. Thus, this report provides 360-degree analysis of key elements such as drivers, growth opportunities, trends, challenges, threats, and restraints in the market. Moreover, this study document provides reliable data on sales, production, volume, shares, and revenues of the market for AI-based clinical trials solution provider.
The study performs segmentation of the global AI-based clinical trials solution provider market based on several important parameters such as clinical trial phase, therapeutic application, end-user, and region. On the basis of therapeutic application, the global AI-based clinical trials solution provider market is classified into cardiovascular diseases, oncology, metabolic diseases, infectious diseases, neurological diseases or conditions, and others.
In recent years, several organizations from private as well as public sectors across the globe are increasing initiatives to support different R & D activities pertaining to therapeutic areas. This factor is anticipated to boost growth avenues in the global AI-based clinical trials solution provider market in the upcoming years.
The penetration of artificial intelligence (AI) is increasing across varied industrial verticals including clinical trials. This factor is fueling the demand opportunities in the market for AI-based clinical trials solution provider.
With increasing demand for AI-based clinical trials solutions across the globe, the global AI-based clinical trials solution provider market is experiencing entry of many new players in it. As a result, the competition levels in the market are getting intensified, which motivates market players to engage in different strategic moves such as mergers, acquisitions, joint ventures, partnerships, and collaborations.
Several enterprises in the global AI-based clinical trials solution provider market are investing heavily in the R & D activities. The move is assisting them in the new product development, and thereby new product launch activities. Owing to these factors, the global AI-based clinical trials solution provider market is expected to expand at promising pace in the years to come.
The list of key players in the global AI-based clinical trials solution provider market includes many names such as Saama Technologies, Unlearn.AI, Inc., Phesi, Antidote Technologies, Inc., Innoplexus, Deep 6 AI, Median Technologies, Mendel.ai, Intelligencia, BioAge Labs, Inc., Symphony AI, CONSILX, DEEP LENS AI, and AiCure, LLC.
In terms of region, the global AI-based clinical trials solution provider market is bifurcated into many geographical regions such as Europe, North America, Asia Pacific, Latin America, and Middle East and Africa. Of them, North America is one of the dominant regions in the market for AI-based clinical trials solution provider.
The North America AI-based clinical trials solution provider market is anticipated to experience prodigious expansion opportunities in the years to come. This growth can be attributed to many factors including surge in the number of clinical trials carried out in the region.
Interested in this report?
Get a FREE Brochure now!
*Get Brochure (PDF) sent to your email within minutes
N/A
Complete the form below and we'll get back to you shortly.